Private health insurance and regional Australia

Buddhima Lokuge, Richard Denniss and Thomas A Faunce

ABSTRACT

- Since 1996, an increasing proportion of federal government expenditure has been directed into Australia’s healthcare system via private health insurance (PHI) subsidies, in preference to Medicare and the direct funding of public health services.
- A central rationale for this policy shift is to increase the use of private hospital services and thereby reduce pressure on public inpatient facilities. However, the impact of this reform process on regional Australia has not been addressed.
- An analysis of previously unpublished Australian Bureau of Statistics data shows that regional Australians have substantially lower levels of private health fund membership. As a result, regional areas appear to be receiving substantially less federal government health funding, compared with cities, than if these funds were allocated on a per-capita basis.
- We postulate that the lower level of membership in regional areas is mainly due to the limited availability of private inpatient facilities, making PHI less attractive to rural Australians.
- We conclude that PHI as a vehicle for mainstream federal health financing has potential structural failures that disadvantage regional Australians.

Reorientation towards private health insurance since 1996

While targeted programs can act as short-term boosters to regional health services, their effect is relatively insignificant compared with the regional importance of mainstream health financing policies and programs: Medicare, the Pharmaceutical Benefits Scheme, and private health insurance (PHI) rebates (discussed below).

Since 1996, an increasing proportion of federal government health expenditure has been directed into Australia’s healthcare system via PHI subsidies in the form of tax rebates. In so doing, the government aims to expand the level of PHI coverage, thereby encouraging the use of private hospital services and reducing pressure on public hospitals. An important part of these policy reforms is the non-means-tested 30% PHI rebate, which is estimated to cost the government $2.5 billion per year. As the rebate is uncapped, the public funds diverted to this program increase whenever membership or premiums rise. For instance, on 1 April 2003, the government authorised an average increase in PHI premiums of more than 7%, which is likely to cost taxpayers an extra $170 million per year in the rebate scheme. Moreover, clause 50 of the 1998–2003 Australian Health Care Agreement acts as a “clawback” provision, allowing the federal government to reduce public-hospital funding to the states and territories if PHI membership increases beyond a certain threshold.

These reforms have meant that, since 1996, the federal government’s role in financing private hospitals has substantially increased, both in real terms and in comparison with funding increases to public hospitals. In 1996–97, federal and state governments provided 11% of the total funding for private hospitals in Australia. By 2002–03, primarly as a result of PHI rebates, the contribution of federal and state governments to private hospital funding had risen to 55%. Similarly, over the

Australian National University, Canberra, ACT.
Buddhima Lokuge, MB BS, MPH, Project Director, Centre for Governance of Knowledge and Development; Thomas A Faunce, LLB(Hons), BMed, PhD, Senior Lecturer, Medical School and Law School, Australia Institute, Canberra, ACT.
Richard Denniss, BCom(Hons), PhD, Deputy Director.
Reprints will not be available from the authors. Correspondence: Dr Buddhima Lokuge, Australian National University, 3rd Floor, Coombs Building Extension, Cnr Fellows and Garran Roads, Canberra, ACT 0200, buddhima.lokuge@anu.edu.au
1 Proportion of people covered by private health insurance (PHI) in 2001, by state and region* 

<table>
<thead>
<tr>
<th>State</th>
<th>Capital city</th>
<th>Rest of state</th>
<th>Regional difference in PHI coverage (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSW</td>
<td>50.4%</td>
<td>43.3%</td>
<td>7.1% (2.1%, 12.2%)</td>
</tr>
<tr>
<td>VIC</td>
<td>49.6%</td>
<td>41.0%</td>
<td>8.6% (1.9%, 15.2%)</td>
</tr>
<tr>
<td>QLD</td>
<td>45.4%</td>
<td>45.0%</td>
<td>0.4% (-3.3%, 6.1%)</td>
</tr>
<tr>
<td>SA</td>
<td>50.5%</td>
<td>41.7%</td>
<td>8.8% (-0.4%, 18.0%)</td>
</tr>
<tr>
<td>WA</td>
<td>53.9%</td>
<td>48.5%</td>
<td>5.4% (-2.3%, 13.1%)</td>
</tr>
<tr>
<td>TAS</td>
<td>56.7%</td>
<td>43.0%</td>
<td>13.7% (4.3%, 23.0%)</td>
</tr>
<tr>
<td>National mean</td>
<td>50.2%</td>
<td>43.5%</td>
<td>6.7% (4.3%, 9.0%)</td>
</tr>
</tbody>
</table>

*From unpublished Australian Bureau of Statistics (ABS) data derived from the National Health Survey. † People covered by PHI refers to anyone with hospital cover, including those with hospital cover only and those with hospital and ancillary cover. Separate estimates for the Northern Territory and Australian Capital Territory were not available for this survey, but contribute to national estimates. § Confidence intervals are based on relative standard errors provided by the ABS.

Second, a structural reason why PHI membership is less attractive to residents of regional areas is the limited availability of private facilities. The central reason to purchase PHI cover is to have affordable access to private hospital facilities. ABS and AHW statistics on hospitals and bed numbers by location indicate that private facilities are concentrated in urban areas (Box 3).

Across Australia, only 16% of hospitals located outside major cities are private facilities. Of the available inpatient beds outside major cities, only 24% are located within private hospitals (Box 4). Not surprisingly, the bulk of patients requiring hospital admission in regional areas are treated within the public sector (Box 5). These findings highlight the fact that private hospital providers prefer (like banks and other commercial institutions) to concentrate facilities in areas of high population and service demand, often neglecting less profitable rural and remote areas with equal healthcare needs. These data suggest that PHI rebates funded through general taxation are unlikely to reduce the load on public hospitals in regional areas, as private facilities are often not available as substitutes. Additionally, as the Senate Select Committee on Medicare concluded in its 2003 report, regional Australians who are currently encouraged by the tax system to take up PHI despite limited opportunities for utilisation of private health services “effectively subsidise the PHI industry at the expense of their local public health services”.

Finally, given that the level of PHI membership is higher in cities, it is likely that increased coverage as a result of reforms since 1997 has translated into disproportionately more private services being purchased from facilities located in cities than regional areas. The impact that this is likely to have on investment and location decisions of private hospitals since 1997 is to further increase the urban–rural disparity of public–private beds and services.

Private health insurance in rural and remote Australia

In June 2003, we commissioned the Australian Bureau of Statistics (ABS) to supply previously unpublished data on the proportion of people with PHI living in or outside capital cities in each state.

The ABS analysis shows that PHI membership is lower outside capital cities — a statistically significant average of 6.7 percentage points Australia-wide (Box 1). The difference is greatest in Tasmania and least in Queensland (where a large proportion of the population resides in sizeable urban centres such as Townsville, the Sunshine Coast and Rockhampton). A previous survey by the ABS in 1998 found a similar regional disparity in PHI membership (an Australia-wide aggregate of 34.9% in capital cities and 28.0% in other areas).

We estimate that the cost of the PHI rebate to regional Australia may exceed $100 million a year (Box 2).

Economics of private health insurance in regional Australia

There are two principal reasons for the urban–rural membership differences observed in our analysis; these relate to affordability and choice. First, income is one of the strongest predictors of PHI uptake, and average incomes are lower in regional than in urban areas. Multiple studies show that there is a clear income gradient to the uptake of PHI, with lower income groups less likely to have PHI. As a result, PHI as a mechanism for federal health funding disadvantages regional communities, compared with, for example, the distribution of funds on a per-capita basis.

Second, a structural reason why PHI membership is less attractive to residents of regional areas is the limited availability of private facilities. The central reason to purchase PHI cover is to have affordable access to private hospital facilities. ABS and AHW statistics on hospitals and bed numbers by location indicate that private facilities are concentrated in urban areas (Box 3).

Across Australia, only 16% of hospitals located outside major cities are private facilities. Of the available inpatient beds outside major cities, only 24% are located within private hospitals (Box 4). Not surprisingly, the bulk of patients requiring hospital admission in regional areas are treated within the public sector (Box 5). These findings highlight the fact that private hospital providers prefer (like banks and other commercial institutions) to concentrate facilities in areas of high population and service demand, often neglecting less profitable rural and remote areas with equal healthcare needs. These data suggest that PHI rebates funded through general taxation are unlikely to reduce the load on public hospitals in regional areas, as private facilities are often not available as substitutes. Additionally, as the Senate Select Committee on Medicare concluded in its 2003 report, regional Australians who are currently encouraged by the tax system to take up PHI despite limited opportunities for utilisation of private health services “effectively subsidise the PHI industry at the expense of their local public health services”.

Finally, given that the level of PHI membership is higher in cities, it is likely that increased coverage as a result of reforms since 1997 has translated into disproportionately more private services being purchased from facilities located in cities than regional areas. The impact that this is likely to have on investment and location decisions of private hospitals since 1997 is to further increase the urban–rural disparity of public–private beds and services.

Period 1996–97 to 2002–03, federal government funding of public hospitals grew at a real annual rate of 8%, compared with 6% for private facilities.

We believe that, in the ongoing shift towards PHI as a means of healthcare financing, the federal government has failed to address the impact of this policy change on regional Australia. We conducted a study to examine the likely distributional effect of the reforms for regional inpatient funding and access to services.

Private health insurance in rural and remote Australia

In June 2003, we commissioned the Australian Bureau of Statistics (ABS) to supply previously unpublished data on the proportion of people with PHI living in or outside capital cities in each state.

The ABS analysis shows that PHI membership is lower outside capital cities — a statistically significant average of 6.7 percentage points Australia-wide (Box 1). The difference is greatest in Tasmania and least in Queensland (where a large proportion of the population resides in sizeable urban centres such as Townsville, the Sunshine Coast and Rockhampton). A previous survey by the ABS in 1998 found a similar regional disparity in PHI membership (an Australia-wide aggregate of 34.9% in capital cities and 28.0% in other areas).

We estimate that the cost of the PHI rebate to regional Australia may exceed $100 million a year (Box 2).

Economics of private health insurance in regional Australia

There are two principal reasons for the urban–rural membership differences observed in our analysis; these relate to affordability and choice. First, income is one of the strongest predictors of PHI uptake, and average incomes are lower in regional than in urban areas. Multiple studies show that there is a clear income gradient to the uptake of PHI, with lower income groups less likely to have PHI. As a result, PHI as a mechanism for federal health funding disadvantages regional communities, compared with, for example, the distribution of funds on a per-capita basis.

Second, a structural reason why PHI membership is less attractive to residents of regional areas is the limited availability of private facilities. The central reason to purchase PHI cover is to have affordable access to private hospital facilities. ABS and AHW statistics on hospitals and bed numbers by location indicate that private facilities are concentrated in urban areas (Box 3).

Across Australia, only 16% of hospitals located outside major cities are private facilities. Of the available inpatient beds outside major cities, only 24% are located within private hospitals (Box 4). Not surprisingly, the bulk of patients requiring hospital admission in regional areas are treated within the public sector (Box 5). These findings highlight the fact that private hospital providers prefer (like banks and other commercial institutions) to concentrate facilities in areas of high population and service demand, often neglecting less profitable rural and remote areas with equal healthcare needs. These data suggest that PHI rebates funded through general taxation are unlikely to reduce the load on public hospitals in regional areas, as private facilities are often not available as substitutes. Additionally, as the Senate Select Committee on Medicare concluded in its 2003 report, regional Australians who are currently encouraged by the tax system to take up PHI despite limited opportunities for utilisation of private health services “effectively subsidise the PHI industry at the expense of their local public health services”.

Finally, given that the level of PHI membership is higher in cities, it is likely that increased coverage as a result of reforms since 1997 has translated into disproportionately more private services being purchased from facilities located in cities than regional areas. The impact that this is likely to have on investment and location decisions of private hospitals since 1997 is to further increase the urban–rural disparity of public–private beds and services.

2 Regional cost of the private health insurance (PHI) rebate

- In 2001, 50.2% of people living in Australian capital cities were covered by PHI compared with 43.5% living outside capital cities. The 6.7 percentage-point gap between the two equates to 350 875 less people having PHI in regional areas.
- Data on average PHI premiums are difficult to obtain because of the wide range of factors that affect pricing, such as the number of people covered by each policy, the existence of an “excess”, and the range of ancillary services covered.
- Some data are available from the Private Health Insurance Administration Council (PHIAC). According to the PHIAC, the average level of contribution to PHI was $34.64 per member in 2001–02. Given that premiums rose by an average 7.4% in April 2003, the average premium per person covered would now be about $896.40.
- If 350 875 people living outside capital cities were to take out PHI at an average cost of $896.40 per person covered, the additional cost to the federal government of its 30% PHI rebate would be $94.4 million per year (assuming the mix of hospital-only and hospital-plus-ancillary policies remained constant). This figure is likely to be an underestimate, as the average price of PHI is lowered by people who take out “ancillary only” health insurance policies, such as ambulance cover. Such policies are substantially cheaper than hospital cover and do not attract the government’s 30% PHI rebate. Thus, the cost to regional Australia of the government’s reliance on the PHI rebate to distribute resources is likely to exceed $100 million a year.
CONCLUSIONS

We have not attempted to consider the regional effects of all health financing systems in Australia. By focusing on PHI, we hope to highlight the point that, although targeted initiatives have a role in addressing regional inequities, it is far more important to ensure that mainstream policies and programs do not institutionally discriminate against disadvantaged groups. In recognition of this, initiatives are being developed in Australia and other countries to ensure that mainstream policy reforms take into account the impact on disadvantaged communities.

We have highlighted some of the structural failures of a PHI rebate scheme. PHI subsidies are a non-universal and indirect means of channelling public expenditures into the healthcare system. This approach gives governments only limited control over the regional and demographic distribution of funds, disadvantaging groups who are less likely to use or benefit from PHI, including those on low incomes and Indigenous Australians. While Medicare has limitations, its universality and the direct nature of hospital funding allow greater flexibility to promote equitable and needs-based distribution of funds.

Acknowledgements

We wish to thank the Australia Institute for the purchase of original data used in this study from the Australian Bureau of Statistics.

Competing interests

None identified.

References

FOR DEBATE


(Received 20 Oct 2004, accepted 17 Jan 2005)

BOOK REVIEW

Reefer madness


THE RELATIONSHIP BETWEEN marijuana use and mental illness is a hotly debated topic. Tabloid headlines refer to “supergrass” causing schizophrenia, while alternative lifestyle enthusiasts claim medicinal properties for marijuana. Social conservatives argue it is a pernicious drug that leads to harder drug use, while social progressives use its ubiquity to argue that much of the harm associated with its use comes from its criminalised status. A book that cuts through the polemic and takes a scientific view is most welcome.

Castle and Murray are widely published psychiatrists (from Australia and the United Kingdom, respectively). They have assembled 13 chapters, prepared by international experts, examining the links between cannabis use and mental illness, especially psychosis.

The book opens with an exploration of exogenous cannabinoids and the endogenous cannabinoid system in the brain. It goes on to explore the links between cannabis use and psychosis, with particular emphasis on schizophrenia. There are also chapters discussing depression and anxiety disorders allegedly associated with marijuana use, and whether there is a specific cannabis psychosis. Two groups explore research linking the endogenous cannabinoid system and schizophrenia. The book closes with contributions of immediate clinical relevance. These examine the motives that sustain cannabis misuse in individuals with psychoses, some strategies for addressing cannabis misuse in this population, and the residual cognitive effects of long-term cannabis use.

Despite the dedication “to Francis Ames, whose belief in the potential medical and environmental benefits of marijuana was never obscured by the smoke of political rhetoric”, a balanced approach to the subject is taken. The text is dense and heavily referenced. A great deal of attention is paid to the careful methodologies and their limitations. The conclusions drawn by each group are understandably cautious. I found this an interesting compilation of research covering a poorly understood area of great clinical relevance. Doctors who work in this field could benefit themselves up to date on a large body of research by reading this book. With cannabis use continuing to rise and the causes of schizophrenia continuing to elude us, I am sure this will be an expanding field.

Joshua D Geffen
Psychiatrist, Brisbane, QLD

MJA • Volume 182 Number 6 • 21 March 2005 293